<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="865">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00207337</nctid>
  <trial_identification>
    <studytitle>Exhale (R) Stent for Emphysema</studytitle>
    <scientifictitle>A Prospective Feasibility Study to Evaluate the Safety and Performance of the Exhale(R) Drug-Eluting Stent System in Patients With Emphysema</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>0304-28</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Emphysema</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Exhale Drug-Eluting Stent

Treatment: devices: Exhale Drug-Eluting Stent


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Procedural and technical success - operatively</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Decrease in residual volume &gt; 300mL from baseline</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dyspnea scoring</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary function measures</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise tolerance</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life measures</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. High resolution computed tomography (CT) scan evidence of bilateral emphysema

          2. Residual volume (RV) = 220% predicted.

          3. Total lung capacity (TLC) = 133% of predicted value.

          4. Forced expiratory volume (FEV1) &lt; 40% of predicted or FEV1 &lt; 1 liter.

          5. Marked dyspnea, scoring = 2 on the modified Medical Research Council scale of 0-4.

          6. Patient has undergone pulmonary rehabilitation of 16 - 20 sessions.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. FEV1 &gt; 20%

          2. Diffusing capacity for carbon monoxide (DLco) &lt; 15% of predicted.

          3. Respiratory infection requiring &gt; 3 hospitalizations in past year

          4. Inability to walk &gt; 140 meters in 6 minutes

          5. Giant bulla &gt; 1/3 of one lung's volume

          6. Previous lung volume reduction surgery (LVRS) or lobectomy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>The Prince Charles Hospital - Rode Road, Chermside</hospital>
    <hospital>The Alfred Hospital - Prahran</hospital>
    <hospital>Concord Repatriation General Hospital - Burwood</hospital>
    <postcode>4032 - Rode Road, Chermside</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>2134 - Burwood</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saarland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Broncus Technologies</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Current treatment for emphysema is limited to measures that include inhaled oxygen,
      bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation. Highly invasive
      procedures such as lung volume reduction surgery or lung transplantation are also performed.
      Treatment using the Exhale Drug-Eluting Stent (DES) is a minimally invasive bronchoscopic
      treatment that has the potential to reduce shortness of breath in emphysema patients. This
      study tests the safety and effects of Exhale DES in the treatment of patients with emphysema.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00207337</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregory I. Snell, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>